Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies

The design and development of therapeutic monoclonal antibodies (mAbs) through optimizing their pharmacokinetic (PK) and pharmacodynamic (PD) properties is crucial to improve efficacy while minimizing adverse events. Many of these properties are interdependent, which highlights the inherent challeng...

Descripción completa

Detalles Bibliográficos
Autores principales: Leipold, Douglas, Prabhu, Saileta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440574/
https://www.ncbi.nlm.nih.gov/pubmed/30414357
http://dx.doi.org/10.1111/cts.12597
_version_ 1783407412210827264
author Leipold, Douglas
Prabhu, Saileta
author_facet Leipold, Douglas
Prabhu, Saileta
author_sort Leipold, Douglas
collection PubMed
description The design and development of therapeutic monoclonal antibodies (mAbs) through optimizing their pharmacokinetic (PK) and pharmacodynamic (PD) properties is crucial to improve efficacy while minimizing adverse events. Many of these properties are interdependent, which highlights the inherent challenges in therapeutic antibody design, where improving one antibody property can sometimes lead to changes in others. Here, we discuss optimization approaches for PK/PD properties of therapeutic mAbs.
format Online
Article
Text
id pubmed-6440574
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-64405742019-04-11 Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies Leipold, Douglas Prabhu, Saileta Clin Transl Sci Reviews The design and development of therapeutic monoclonal antibodies (mAbs) through optimizing their pharmacokinetic (PK) and pharmacodynamic (PD) properties is crucial to improve efficacy while minimizing adverse events. Many of these properties are interdependent, which highlights the inherent challenges in therapeutic antibody design, where improving one antibody property can sometimes lead to changes in others. Here, we discuss optimization approaches for PK/PD properties of therapeutic mAbs. John Wiley and Sons Inc. 2018-12-27 2019-03 /pmc/articles/PMC6440574/ /pubmed/30414357 http://dx.doi.org/10.1111/cts.12597 Text en © 2018 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Reviews
Leipold, Douglas
Prabhu, Saileta
Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies
title Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies
title_full Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies
title_fullStr Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies
title_full_unstemmed Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies
title_short Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies
title_sort pharmacokinetic and pharmacodynamic considerations in the design of therapeutic antibodies
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440574/
https://www.ncbi.nlm.nih.gov/pubmed/30414357
http://dx.doi.org/10.1111/cts.12597
work_keys_str_mv AT leipolddouglas pharmacokineticandpharmacodynamicconsiderationsinthedesignoftherapeuticantibodies
AT prabhusaileta pharmacokineticandpharmacodynamicconsiderationsinthedesignoftherapeuticantibodies

Ejemplares similares